Research programme: cytokine-based immunotherapeutics - Intrexon/ZIOPHARM

Drug Profile

Research programme: cytokine-based immunotherapeutics - Intrexon/ZIOPHARM

Latest Information Update: 05 Oct 2015

Price : $50

At a glance

  • Originator Intrexon Corporation; ZIOPHARM Oncology
  • Class Cell therapies; Interleukins; T lymphocyte cell therapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Graft-versus-host disease

Most Recent Events

  • 29 Sep 2015 Intrexon and ZIOPHARM Oncology agree to co-develop cytokine-based immunotherapeutics in USA for Graft-versus-host disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top